Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Domenico Russo(University of Brescia), Cyrus Badshah(Merck & Co., Inc., Rahway, NJ, USA (United States)), Valerie Teal(Merck & Co., Inc., Rahway, NJ, USA (United States)), Sanjeet Dadwal(City Of Hope National Medical Center), Toshiro Kawakita(Kumamoto Medical Center), Michael Henry Schmitt(Heidelberg University), Charlene Bopp(Merck & Co., Inc., Rahway, NJ, USA (United States)), Matthias Stelljes(University Hospital Münster), Barbara Haber(Merck & Co., Inc., Rahway, NJ, USA (United States)), Sylvain Pilorge(Institut Gustave Roussy)
Cited by 100
Related Papers
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
|New England Journal of Medicine|2017|1.2k
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
|The Lancet Haematology|2020|553
Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial)
|Journal of Clinical Oncology|2017|248
Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with endemic human coronaviruses
|Cell Reports Medicine|2021|219